| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18438 R78184 |
Lee (Controls exposed to TCAs), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
1.09 [0.86;1.38] C excluded (control group) |
216/643 194/613 | 410 | 643 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18420 R77942 |
Lee (Controls unexposed, general pop), 2025 | Cesarean delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.16 [0.98;1.37] | 216/643 111,640/463,440 | 111,856 | 643 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7699 R22873 |
Kivistö, 2016 | Caesarean | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.23 [0.58;2.60] | -/49 4,216/24,402 | - | 49 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7178 R20152 |
Colvin, 2011 | Caesarean (emergency and elective) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 1.07 [0.95;1.20] C | 449/1,340 29,801/92,995 | 30,250 | 1,340 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.10 [1.00;1.21] | 142,106 | 2,032 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 18438